Literature DB >> 24737078

Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells.

Steven C L Ho1, Yuansheng Yang.   

Abstract

Promoters are essential on plasmid vectors to initiate transcription of the transgenes when generating therapeutic recombinant proteins expressing mammalian cell lines. High and sustained levels of gene expression are desired during therapeutic protein production while gene expression is useful for cell engineering. As many finely controlled promoters exhibit cell and product specificity, new promoters need to be identified, optimized and carefully evaluated before use. Suitable promoters can be identified using techniques ranging from simple molecular biology methods to modern high-throughput omics screenings. Promoter engineering is often required after identification to either obtain high and sustained expression or to provide a wider range of gene expression. This review discusses some of the available methods to identify and engineer promoters for therapeutic recombinant protein expression in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24737078     DOI: 10.1007/s10529-014-1523-4

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  4 in total

1.  Early integration of Design of Experiment (DOE) and multivariate statistics identifies feeding regimens suitable for CHO cell line development and screening.

Authors:  Alessandro Mora; Bernard Nabiswa; Yuanyuan Duan; Sheng Zhang; Gerald Carson; Seongkyu Yoon
Journal:  Cytotechnology       Date:  2019-11-09       Impact factor: 2.058

2.  Toward stable gene expression in CHO cells.

Authors:  Esther Y C Koh; Jessna H M Yeo; Steven C L Ho; Yuansheng Yang
Journal:  Bioengineered       Date:  2014 Sep-Oct       Impact factor: 3.269

3.  Molecular switching system using glycosylphosphatidylinositol to select cells highly expressing recombinant proteins.

Authors:  Emmanuel Matabaro; Zeng'an He; Yi-Shi Liu; Hui-Jie Zhang; Xiao-Dong Gao; Morihisa Fujita
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

4.  High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies.

Authors:  Jicong Cao; Eva Maria Novoa; Zhizhuo Zhang; William C W Chen; Dianbo Liu; Gigi C G Choi; Alan S L Wong; Claudia Wehrspaun; Manolis Kellis; Timothy K Lu
Journal:  Nat Commun       Date:  2021-07-06       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.